Posted: Monday, March 15, 2021. 1:43 pm CST.
By Zoila Palma: Final data from the third phase of the Novavax COVID-19 vaccine study revealed that after evaluation, the vaccine was 96.4% effective against mild, moderate, and severe disease caused by the original COVID-19 strain in the United Kingdom.
In addition, Yahoo News reports that the company’s phase IIb study demonstrated that the vaccine candidate delivered 55.4% efficiency among the HIV-negative study participants.
The Novavax vaccine also showed 100% protection against severe disease and significantly reduced mild and moderate diseases across both the studies.
The company is now seeking to submit the data for authorization to several regulatory agencies worldwide.
The Novavax vaccine has also shown 86% efficacy against the new circulating variant, B.1.1.7/501Y.V1, in the United Kingdom.
Several other companies have launched vaccines for fighting COVID-19.
Аdvеrtіѕе wіth thе most visited news site in Веlіzе ~ Wе оffеr fullу сuѕtоmіzаblе аnd flехіblе dіgіtаl mаrkеtіng расkаgеѕ. Yоur соntеnt іѕ dеlіvеrеd іnѕtаntlу tо thоuѕаndѕ оf uѕеrѕ іn Веlіzе аnd аbrоаd! Соntасt uѕ аt firstname.lastname@example.org оr саll uѕ аt 501-601-0315.
© 2021, BreakingBelizeNews.com. This article is the copyrighted property of Breaking Belize News. Written permission must be obtained before reprint in online or print media. REPRINTING CONTENT WITHOUT PERMISSION AND/OR PAYMENT IS THEFT AND PUNISHABLE BY LAW.